Thesis (Ph. D.)--Cornell University, May, 2007. / Vita. Includes bibliographical references (leaves 324-341).

The HECT E3 ubiquitin ligase Nedd4-1 was previously shown to regulate diverse processes such as cell and animal growth, insulin signaling, and lysosomal trafficking. To further elucidate the cellular functions of Nedd4-1, Nedd4-1 knockout mouse embryonic fibroblasts were characterized relative to their wild type counterparts. Immunofluorescence experiments revealed an altered lysosomal distribution in the knockout cells, although their lysosomal proteolytic function appeared normal. Transmission Electron Microscopy revealed striking morphological differences, especially regarding the lysosome and endoplasmic reticulum of the knockout cells. Another aspect of my studies examined the interaction between Nedd4-1 and Angiomotin (p130-AMOT), which involves the same motifs required to sequester transcriptional co-activators YAP and TAZ in the cytoplasm. To test either a competitive or non-competitive mode of binding, co-immunoprecipitation experiments involving p130-AMOT, the Nedd4 proteins, and YAP or TAZ were performed, with results not supporting a competitive mode of interaction. Overall, my results demonstrate new Nedd4-1 cellular functions.

Apoptose ist eine bestimmte Art des programmierten Zelltods. Dieser Prozess erfüllt zahlreiche wichtige physiologische Funktionen. Eine pathologische Dysregulation der Apoptose ist an der Entstehung etlicher Krankheiten beteiligt. Bei der Regulation der Apoptose nehmen die Bcl-2-Familienmitglieder und damit auch das anti-apoptotisches Familienmitglied A1 eine wichtige Stellung ein. Die Stabilität und anti-apoptotische Funktion von A1 wird über den Ubiquitin-Proteasomen-Weg reguliert. Hierbei ist das C-terminale Ende von A1 essentiell. Ausgangspunkt für diese Arbeit war die Hypothese, dass an den C-Terminus von A1 eine bisher unbekannte Ubiquitin-E3-Ligase bindet, verzweigte Ubiquitinketten an Lysinreste des A1-Proteins konjugiert und das Protein dadurch für den proteasomalen Abbau markiert. Durch Mutationen einzelner Lysinreste von A1 sollte untersucht werden, welche dieser Aminosäuren ubiquitinyliert werden. Damit sollte der molekulare Mechanismus, der hinter der Instabilität und der anti-apoptotischen Funktion steckt, weiter charakterisiert werden. In dieser Arbeit wurden insgesamt 11 Mutanten des A1-Proteins hergestellt, bei denen die 11 Lysinreste von A1 gruppenweise zu Argininresten (K-A1-Mutanten) ausge-tauscht wurden. Der Austausch von Lysin zu Arginin wurde gewählt, weil hierdurch die Ladung an der entsprechenden Position des Proteins gleich bleibt, während eine Konjugation von Ubiquitin an Arginin nicht möglich ist. Im Ergebnis zeigte sich, dass das A1-Protein nicht nur an einzelnen, ganz spezifischen Lysinen, sondern an allen oder doch zumindest den meisten seiner 11 Lysine ubiquitinyliert werden kann, denn es ergaben sich bei den K-A1-Mutanten keine signifikanten Unterschiede in Stärke oder Muster ihrer Ubiquitinylierung. Es müssen also nicht einige wenige Lysine notwendigerweise ubiquitinyliert werden, um A1 zu destabilisieren, sondern die Ubiquitinylierung ganz unterschiedlicher Lysine markiert das Protein für den proteasomalen Abbau. Auch hat der Verlust bestimmter Lysingruppen und damit potentieller Ubiquitinylierungsstellen keinen signifikanten Einfluss auf die anti-apoptotische Funktion des A1-Proteins. Zusammengefasst unterstützen die Ergebnisse die Hypothese, dass eine bisher nicht bekannte Ubiquitin-E3-Ligase sowohl die Stabilität als auch die anti-apoptotische Funktion von A1 reguliert, indem sie verzweigte Ubiquitinketten an (fast) alle Lysine des Protein anhängt und das Protein damit für den proteasomalen Abbau markiert. / Apoptosis is a certain kind of programmed cell death and plays an important role in many physiological processes. Pathological dysregulation of apoptosis is involved in the development of a number of diseases. The Bcl-2 family members and with it the anti-apoptotic family member A1 are important regulators of apoptosis by regulating the integrity of the mitochondria. A1 is a very unstable protein, its stability is regulated by the ubiquitin/proteasome pathway. Based on published work, the hypothesis was set up, that a so far unknown ubiquitin-E3-ligase binds to the C-terminal end of A1, attaches ubiquitin chains to lysine residues and thereby marks the protein for proteasomal degradation. The ubiquitinylation and the molecular mechanisms behind the instability and the anti-apoptotic capacity of A1 should be further characterized by mutating the lysine residues of the protein. For this paper altogether 11 mutants of the A1 protein were cloned. The 11 lysine residues of A1 were replaced in groups with arginine residues (K-A1 mutants). Arginine was chosen to keep the charge at that position in the protein but to inhibit ubiquitylation at this position. The experiments indicate that all or at least most of the lysine residues of the A1 protein can be ubiquitinylated, because no significant differences in ubiquitinylation of the K-A1 mutants compared to A1 wildtype protein could be observed. Thus, no specific lysine residues have to be necessarily ubiquitinylated to destabilize the A1 protein, but ubiquitinylation of different lysine residues can mark the protein for proteasomal degradation. Furthermore, the loss of certain lysines showed no significant influence on the anti-apoptotic capacity of A1. Altogether, the results support the hypothesis, that a so far unknown ubiquitin-E3-ligase attaches ubiquitin to most if not all lysine residues and thereby regulates the stability and the anti-apoptotic capacity of the protein.

Camptothecin and its analogues (CPTs) represent one of the most potent classes of anticancer drugs used to treat several solid tumors. CPTs bind topoisomerase I during the replication process and cause DNA damage that results in cell death. However, its effectiveness is limited to 13-30 percent of patients. TopoI cuts and re-ligates DNA supercoiling but in the presence of CPT it fails to re-ligate DNA and collision of replication forks leads to DNA double strand break (DNA-DSB) and cell death. However, in resistant cells, due to deregulated kinase cascade, topoI is continually phosphorylated by DNA-PKcs and rapidly degraded by the ubiquitin proteasomal pathway (UPP). It has been found that BRCA1 plays a key role in imparting cellular resistance to topoI inhibitors. Importantly, BRCA1 ubiquitinates topoI in response to CPT. We hypothesize that disruption of BRCA1 binding to phosphorylated topoI would interrupt the resistance mechanism resulting in higher cellular sensitivity of CPT. Based on an in-silico drug screen, we identified a compound that inhibits topoI degradation by blocking BRCA1 binding. Imaging and survival assays findings are consistent with the hypothesis that BRCA1 plays a role in CPT resistance through its co-localization with topoI, and we speculate this role is through UPP degradation. CPTs are commonly used in combination with cytotoxic compounds, but this study focuses on discovering compounds that can overcome resistance without causing further cytotoxicity. / 2019-07-03T00:00:00Z

Protein quality control systems protect cells against the accumulation of toxic misfolded proteins by promoting their selective degradation. Malfunctions of quality control systems are linked to aging and neurodegenerative disease. Folding of polypeptides is facilitated by the association of 70 kDa Heat shock protein (Hsp70) molecular chaperones. If folding cannot be achieved, Hsp70 interacts with ubiquitylation enzymes that promote the proteasomal degradation of the misfolded protein. However, the factors that direct Hsp70 substrates toward the degradation machinery have remained unknown. Here, we identify Fes1, an Hsp70 nucleotide exchange factor of hitherto unclear physiological function, as a cytosolic triaging factor that promotes proteasomal degradation of misfolded proteins. Fes1 selectively interacts with misfolded proteins bound by Hsp70 and triggers their release from the chaperone. In the absence of Fes1, misfolded proteins fail to undergo polyubiquitylation, aggregate, and induce a strong heat shock response. Our findings reveal that Hsp70 direct proteins toward either folding or degradation by using distinct nucleotide exchange factors.

Drosophila Nedd4 (DNedd4), an E3 ubiquitin ligase, is known to be involved in neuromuscular (NM) synaptogenesis during embryogenesis. To further elucidate its mechanism and function in this process, two major splice isoforms, dNedd4 short (dNedd4S) and dNedd4 long (dNedd4L), were studied. My work shows that while dNedd4S positively regulates NM synaptogenesis, dNedd4L plays a negative role in this process. Unique regions in dNedd4L, including the N-terminal 66 amino acid-long sequence (but not the putative dAkt phosphorylation site) and the middle 159 amino acid-long sequence, as well as the catalytic site, are required for its negative function. I proposed one possible mechanism of dNedd4L acting as a negative regulator of dNedd4S. Results from my studies of the putative effect of dNedd4L on the catalytic activity of dNedd4S in vitro, as well as on the function of dNedd4S towards Comm in Drosophila S2 cells, did not support this mechanism.

Drosophila Nedd4 (DNedd4), an E3 ubiquitin ligase, is known to be involved in neuromuscular (NM) synaptogenesis during embryogenesis. To further elucidate its mechanism and function in this process, two major splice isoforms, dNedd4 short (dNedd4S) and dNedd4 long (dNedd4L), were studied. My work shows that while dNedd4S positively regulates NM synaptogenesis, dNedd4L plays a negative role in this process. Unique regions in dNedd4L, including the N-terminal 66 amino acid-long sequence (but not the putative dAkt phosphorylation site) and the middle 159 amino acid-long sequence, as well as the catalytic site, are required for its negative function. I proposed one possible mechanism of dNedd4L acting as a negative regulator of dNedd4S. Results from my studies of the putative effect of dNedd4L on the catalytic activity of dNedd4S in vitro, as well as on the function of dNedd4S towards Comm in Drosophila S2 cells, did not support this mechanism.

The ubiquitination pathway regulates virtually all cellular processes such as cell cycle control and immune surveillance in eukaryotes, and is thus highly regulated through a variety of means. For instance, the Cullin-RING ubiquitin E3 ligases are regulated by neddylation through the action of a newly identified protein Dcn1. In chapter two, I describe an X-ray crystal structure of yeast Dcn1, encompassing an N-terminal ubiquitin association (UBA) domain and a C-terminal domain of unique architecture, which I termed the PONY (POtentiating NeddYlation) domain. I describe the identification of the reciprocal, conserved binding surfaces on both Dcn1 and yeast cullin Cdc53. In collaboration with Dr. Matthias Peter’s group (ETH Zurich), we show that Dcn1 is necessary and sufficient for cullin neddylation in a purified recombinant system. Together, our data identify Dcn1 as the long sought-after Nedd8 E3 ligase for cullin neddylation. As a modulator of immune surveillance and inflammatory responses, the ubiquitin system serves as an attractive target for subversion by pathogens. In chapter three, I present a structural and functional analysis of a newly identified bacterial ubiquitin E3 ligase IpaH, present in various pathogenic and commensal bacteria. I demonstrate that the leucine-rich repeat (LRR) substrate recognition domains of different IpaH enzymes auto-inhibit the enzymatic activity of the adjacent catalytic domain by two distinct but conserved structural mechanisms. Auto-inhibition is required for the biological activity of two IpaH enzymes in a yeast model system. Retro-engineering of auto-inhibition into a constitutively active IpaH enzyme from Yersinia demonstrates that most of the infrastructure required to support auto-inhibition is evolutionarily conserved. In brief, my research provides insights into the mechanism of action of two newly identified protein ligases in the ubiquitination pathway, namely the Nedd8 E3 ligase Dcn1 and bacterial ubiquitin E3 ligase IpaH.

The ubiquitination pathway regulates virtually all cellular processes such as cell cycle control and immune surveillance in eukaryotes, and is thus highly regulated through a variety of means. For instance, the Cullin-RING ubiquitin E3 ligases are regulated by neddylation through the action of a newly identified protein Dcn1. In chapter two, I describe an X-ray crystal structure of yeast Dcn1, encompassing an N-terminal ubiquitin association (UBA) domain and a C-terminal domain of unique architecture, which I termed the PONY (POtentiating NeddYlation) domain. I describe the identification of the reciprocal, conserved binding surfaces on both Dcn1 and yeast cullin Cdc53. In collaboration with Dr. Matthias Peter’s group (ETH Zurich), we show that Dcn1 is necessary and sufficient for cullin neddylation in a purified recombinant system. Together, our data identify Dcn1 as the long sought-after Nedd8 E3 ligase for cullin neddylation. As a modulator of immune surveillance and inflammatory responses, the ubiquitin system serves as an attractive target for subversion by pathogens. In chapter three, I present a structural and functional analysis of a newly identified bacterial ubiquitin E3 ligase IpaH, present in various pathogenic and commensal bacteria. I demonstrate that the leucine-rich repeat (LRR) substrate recognition domains of different IpaH enzymes auto-inhibit the enzymatic activity of the adjacent catalytic domain by two distinct but conserved structural mechanisms. Auto-inhibition is required for the biological activity of two IpaH enzymes in a yeast model system. Retro-engineering of auto-inhibition into a constitutively active IpaH enzyme from Yersinia demonstrates that most of the infrastructure required to support auto-inhibition is evolutionarily conserved. In brief, my research provides insights into the mechanism of action of two newly identified protein ligases in the ubiquitination pathway, namely the Nedd8 E3 ligase Dcn1 and bacterial ubiquitin E3 ligase IpaH.

La synthétase des acides gras (FAS) est une enzyme clef de la lipogenèse hépatique responsable de la synthèse des acides gras saturés à longue chaîne. Cette enzyme est régulée au niveau transcriptionel par les nutriments et les hormones. Ainsi, le glucose, l'insuline et la T3 augmentent son activité alors que les acides gras à moyennes chînes (MCFAs), les acides gras poly-insaturés (PUFAs) et le glucagon la diminuent. Dans des cellules hépatiques, nous avons mis en évidence que la T3 et l'insuline étaient capables d'activer de façon synergique l'activité enzymatique et le niveau d'expression des ARNm de la FAS (14 fois). L'analyse du promoteur a permis de démontrer que cette activation était aussi transcriptionnelle. Par la suite l'élément de réponse à la T3 (TRE) a été localisé dans la région promotrice du gène FAS. Ce TRE fixe un hétérodimère TR/RXR en absence d'hormone et cette fixation est augmentée en présence d'insuline et/ou de T3. L'utilisation de H7, un inhibiteur général des serines/thréonines kinases, nous a permis de mettre en évidence que des mécanismes de phosphorylation sont impliqués dans la régulation transcriptionelle de la FAS par ces deux hormones. En fait, nous avons démontré que la voie de signalisation cellulaire PI3-Kinase/ ERK1/2-MAPK est impliquée dans la régulation de la FAS par la T3 via le TRE. De plus, nous avons aussi mis en évidence un effet de l'insuline sur ce TRE qui impliquerait la même voie de signalisation ainsi qu'une voie qui pourrait aussi impliquer Akt. Les mêmes effets non génomiques de la T3 et de l'insuline sont aussi observés au niveau d'un TRE consensus de type DR4. En conclusion, nos résultats suggèrent que la T3 régule la transcription par un mécanisme d'action à la fois génomique et non génomique impliquant la voie PI3-Kinse/MAPK et que l'insuline est aussi capable de cibler ce TRE par des voies de signalisation spécifiques. ______________________________________________________________________________ MOTS-CLÉS DE L’AUTEUR : FAS, T3, Insuline, PI3-Kinase, Erk1/2-MAPK.